Similar articles

• Medicare program; Medicare prescription drug benefit. Final rule.

  Centers for Medicare & Medicaid Services (CMS), HHS. Centers for Medicare & Medicaid Services (CMS), HHS. Fed Regist. 2005 Jan 28;70(18):4193-585. Fed Regist. 2005. PMID: 15678603
• Chronic conditions and disabilities: trends and issues for private drug plans.

  Boccuti C, Moon M, Dowling K. Boccuti C, et al. Policy Brief Commonw Fund. 2003 Oct;(680):1-10. Policy Brief Commonw Fund. 2003. PMID: 14562797 No abstract available.
• A sustainable future?: the role of premium subsidies in Medicare prescription drug plans.

  Demchak C. Demchak C. Find Brief. 2007 Jan;10(2):1-6. Find Brief. 2007. PMID: 17302011 No abstract available.
• Are women better off because of the new Medicare drug legislation?

  Moon M. Moon M. Womens Health Issues. 2005 Jan-Feb;15(1):1-4. doi: 10.1016/j.whi.2004.10.001. Womens Health Issues. 2005. PMID: 15661581 Review.
• Drug insurance utilization management policies and "reference pricing": an illustrated commentary on the article by Vittorio Maio and colleagues.

  Maclure M. Maclure M. Milbank Q. 2005;83(1):131-47. doi: 10.1111/j.0887-378X.2005.00338.x. Milbank Q. 2005. PMID: 15787956 Free PMC article. Review. No abstract available.